| Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis (NCT05272150) | Janssen Research & Development, LLC | 2022-07-13 |
| A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis (NCT05357755) | Janssen Research & Development, LLC | 2022-06-13 |
| A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis (NCT05364554) | Janssen Research & Development, LLC | 2022-06-10 |
| Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis (NCT05509361) | Akeso | 2022-04-08 |
| Study of Efficacy and Safety of Investigational Treatment in Patients With Nail Psoriasis (NCT05072886) | Azora Therapeutics Australia Pty Ltd | 2022-04-01 |
| Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685 (NCT05332704) | Ono Pharmaceutical Co., Ltd. | 2022-03-25 |
| Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis (NCT05268016) | Meiji Pharma USA Inc. | 2022-03-24 |
| A Study of DLX105-DMP in Subjects With Plaque Psoriasis (NCT04203433) | DelArrivo, Inc. | 2022-03-21 |
| A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis (NCT05223868) | Janssen Research & Development, LLC | 2022-02-03 |
| Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults (NCT05203315) | Austin Institute for Clinical Research | 2022-01-13 |
| Psorcast Mobile Study (NCT05621369) | Sage Bionetworks | 2022-01-01 |
| Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects (NCT05172726) | Organon and Co | 2021-12-02 |
| Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study (NCT04823247) | Almirall, S.A. | 2021-11-22 |
| Exploratory Study to Evaluate the Application of NLAC Cream in Adults With Plaque Psoriasis (NCT05078567) | Microbio Co Ltd | 2021-10-31 |
| A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis (NCT05073315) | Amgen | 2021-10-04 |
| Sequential Treatment of Psoriasis With Traditional Chinese and Western Medicine (NCT05042635) | Shanghai Yueyang Integrated Medicine Hospital | 2021-10-01 |
| A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering From Plaque Psoriasis Through Clinical Utility and Health Outcomes. (NCT05036889) | Mindera Health | 2021-09-24 |
| A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque Psoriasis (NCT06808815) | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | 2021-09-22 |
| Investigation With BiopH+Psoriasis Medical Bath in Subject With Mild to Moderate Plaque Psoriasis. (NCT05046899) | Biocool AB | 2021-09-14 |
| A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis (NCT05442788) | Huabo Biopharm Co., Ltd. | 2021-09-02 |
| Evaluation of the Effect of Sulphur Mineral, Thermal Water on Skin Microbiome in Plaque Psoriasis, a Pilot Study (NCT05431959) | Szeged University | 2021-07-25 |
| Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis (NCT04728360) | Bio-Thera Solutions | 2021-07-06 |
| Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care Hospital. (NCT05891964) | Jinnah Postgraduate Medical Centre | 2021-07-05 |
| A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis (NCT04908514) | Aldeyra Therapeutics, Inc. | 2021-05-07 |
| A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) (NCT04855721) | Aurigene Discovery Technologies Limited | 2021-05-04 |
| A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis. (NCT05282771) | Sun Pharmaceutical Industries, Inc. | 2021-04-16 |
| A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis (NCT04772079) | Bristol-Myers Squibb | 2021-03-23 |
| Guselkumab Immunogenetics (NCT04645355) | University of California, San Francisco | 2021-03-01 |
| Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216) (NCT04746911) | Arcutis Biotherapeutics, Inc. | 2021-03-01 |
| Prevalence of Periodontitis in Patients With Plaque Psoriasis. A Cross-sectional Study (NCT04722094) | University of Siena | 2021-01-25 |
| Comparison of Cyanocobalamin in Avocado Oil Cream With Steroid Combination Ointment (NCT05330936) | Pak Emirates Military Hospital | 2021-01-01 |
| Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis (NCT04571151) | Skin Sciences, PLLC | 2021-01-01 |
| Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis (NCT04664153) | Pfizer | 2020-12-21 |
| A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis (NCT05108766) | Shenzhen Kangzhe Pharmaceutical Co., Ltd. | 2020-12-17 |
| Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab (NCT04533737) | LEO Pharma | 2020-12-17 |
| Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis (NCT04537689) | Singapore General Hospital | 2020-12-10 |
| An Analysis of the Improvement and Quality of Life Trends for UK/ROI Patients Treated With Cosentyx (Secukinumab) in a Retrospective Analysis of the BADBIR Data Source (NCT05368818) | Novartis Pharmaceuticals | 2020-12-07 |
| Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis (NCT04720105) | Icahn School of Medicine at Mount Sinai | 2020-11-19 |
| A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (NCT04607980) | Amgen | 2020-11-11 |
| A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis (NCT04595409) | Bioeq GmbH | 2020-11-09 |
| A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis (NCT04594928) | Lakefront Biotherapeutics NV | 2020-10-19 |
| A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis (NCT04603027) | Evelo Biosciences, Inc. | 2020-09-21 |
| Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis (NCT05344482) | Novartis Pharmaceuticals | 2020-07-09 |
| Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients (NCT04398732) | Pfizer | 2020-07-05 |
| Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO). (NCT04428411) | Pfizer | 2020-07-05 |
| Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis (NCT04453137) | Alvotech Swiss AG | 2020-06-30 |
| A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol) (NCT04163016) | UCB Biopharma SRL | 2020-06-19 |
| A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis (NCT04080206) | Therapeutics, Inc. | 2020-04-07 |
| Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis (NCT04279119) | Arcutis Biotherapeutics, Inc. | 2020-03-10 |
| A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD) (NCT04237116) | Novartis Pharmaceuticals | 2020-02-19 |
| Long-Term Treatment Effect With Tildrakizumab in Participants With Plaque Psoriasis (NCT04339595) | Almirall, S.A. | 2020-01-29 |
| Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis (NCT04173637) | Akeso | 2019-12-19 |
| Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE) (NCT04229836) | Almirall, S.A. | 2019-12-17 |
| A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab (NCT04102007) | AbbVie | 2019-11-12 |
| A Clinical Study of SHR-1314 Injection in the Treatment of Moderate to Severe Plaque Psoriasis in Adults (NCT04121143) | Jiangsu HengRui Medicine Co., Ltd. | 2019-11-09 |
| Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice (NCT04203693) | Almirall, S.A. | 2019-10-30 |
| Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis (NCT04036188) | Wright State University | 2019-10-16 |
| Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy (NCT04263610) | Almirall, S.A. | 2019-09-04 |
| A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice (NCT04053881) | UCB Biopharma SRL | 2019-08-21 |
| Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis (NCT04042103) | Organon and Co | 2019-07-23 |
| A Study to Describe the Characteristics of Patients Treated With Apremilast for Plaque Psoriasis in Italian Routine Clinical Practice (NCT04031027) | Amgen | 2019-07-22 |
| Autologous Natural Killer Cells in Subjects With Plaque Psoriasis (NCT03894579) | NKGen Biotech, Inc. | 2019-07-18 |
| Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS (NCT04018599) | Fresenius Kabi SwissBioSim GmbH | 2019-07-15 |
| A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy (NCT03930186) | Amgen | 2019-06-17 |
| Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis (NCT03992261) | Mayne Pharma International Pty Ltd | 2019-06-14 |
| Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002) (NCT03983980) | Organon and Co | 2019-06-06 |
| Moving Cupping for Plaque Psoriasis: a Randomized Controlled Trial (NCT03952676) | Shanghai Yueyang Integrated Medicine Hospital | 2019-06-01 |
| Sequential Treatment of Psoriasis With Integrated Traditional Chinese and Western Medicine (NCT03941431) | Shanghai Yueyang Integrated Medicine Hospital | 2019-06-01 |
| Fire Needle Therapy on Plaque Psoriasis With Blood Stasis Syndrome (NCT03953885) | Shanghai Yueyang Integrated Medicine Hospital | 2019-06-01 |
| A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases (NCT03858634) | Genentech, Inc. | 2019-05-29 |
| Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis (NCT03837743) | Durect | 2019-02-21 |
| Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis (NCT03849404) | Alvotech Swiss AG | 2019-02-20 |
| Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis (NCT03832738) | Akros Pharma Inc. | 2019-01-17 |
| Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis (NCT03589885) | Novartis Pharmaceuticals | 2018-12-19 |
| Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis (NCT03764475) | Arcutis Biotherapeutics, Inc. | 2018-12-18 |
| A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis (NCT03573323) | Eli Lilly and Company | 2018-11-09 |
| Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307) (NCT03731052) | Therapeutics, Inc. | 2018-10-16 |
| Efficacy and Safety Study of Autonomic Nerve Modulation (ANM) in Subjects With Moderate Plaque Psoriasis (NCT03817164) | Thync Global, Inc. | 2018-10-02 |
| Pain Outcomes Following Intralesional Corticosteroid Injections (NCT03630198) | Vanderbilt University Medical Center | 2018-10-01 |
| A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis (NCT03614078) | PRCL Research Inc. | 2018-09-25 |
| The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis (NCT03638258) | Arcutis Biotherapeutics, Inc. | 2018-09-21 |
| CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis (NCT03168256) | Can-Fite BioPharma | 2018-09-15 |
| A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Plaque Psoriasis in Adults (NCT02993328) | Santalis Pharmaceuticals, Inc. | 2018-06-10 |
| Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast (NCT03442088) | University Hospitals Cleveland Medical Center | 2018-06-01 |
| Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color (NCT03506477) | Icahn School of Medicine at Mount Sinai | 2018-05-21 |
| An Open-Label Study to Assess Safety (NCT03645499) | Sun Pharmaceutical Industries, Inc. | 2018-04-04 |
| A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis (NCT04172233) | Akeso | 2018-01-09 |
| The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients (NCT03848871) | Derm Research, PLLC | 2017-12-12 |
| AGN-242428 in the Treatment of Plaque Psoriasis (NCT03339999) | Vitae Pharmaceuticals, Inc. | 2017-11-15 |
| Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis (NCT03358290) | Akros Pharma Inc. | 2017-11-10 |
| Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis (NCT03316781) | Shanghai Henlius Biotech | 2017-10-27 |
| A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis (NCT03210961) | Pfizer | 2017-07-14 |
| A Trial of a Botanical Drug (EISO) for Treatment of Mild-to-Moderate Plaque Psoriasis (NCT03000608) | Santalis Pharmaceuticals, Inc. | 2017-05-17 |
| A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis (NCT03167515) | Ferndale Laboratories, Inc. | 2017-05-16 |
| Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients (NCT03055494) | Novartis Pharmaceuticals | 2017-04-18 |
| Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis (NCT03073200) | Eli Lilly and Company | 2017-03-28 |
| Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis (NCT03020199) | Novartis Pharmaceuticals | 2017-03-27 |
| Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05% (NCT03212963) | Sun Pharmaceutical Industries Limited | 2017-03-21 |
| Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis (NCT03066609) | Novartis Pharmaceuticals | 2017-02-28 |
| A Comparison of 188-0551 Solution Versus Vehicle Solution in Subjects With Plaque Psoriasis (Study 203) (NCT03065556) | Therapeutics, Inc. | 2017-01-26 |